POZEN (NASDAQ:POZN)
6.95
+0.21 (3.12%)
| POZEN (NASDAQ:POZN) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $6.74 | 52 Week High | $8.42 | ||
| Open | $6.72 | 52 Week Low | $4.50 | ||
| Day High | $6.99 | P/E | N/A | ||
| Day Low | $6.50 | EPS | $-0.18 | ||
| Volume | 222,992 | ||||
| More POZN Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| AZN | 3 | KEX | 2 |
| CTS | 2 | CTS | 2 |
| LSI | 2 | SEPR | 2 |
| DRYS | 2 | SEPR | 2 |
| DRYS | 2 | ISSC | 2 |
| EK | 2 | SIGI | 2 |
Entities who have mentioned POZN
- Citi | View Related Stories »
- Barclays | View Related Stories »
- Jefferies & Co | View Related Stories »
- Dividend | View Related Stories »
- StreetInsider.com Morning Movers | View Related Stories »
- TPG-Axon Capital | View Related Stories »
- Thomas Weisel Partners Group | View Related Stories »
- UBS | View Related Stories »
- Piper Jaffray | View Related Stories »
- KeyBanc | View Related Stories »
- D.A. Davidson | View Related Stories »
- Raymond James | View Related Stories »
- Banc of America | View Related Stories »
- Barron's | View Related Stories »
- JPMorgan | View Related Stories »
- Credit Suisse | View Related Stories »
- Brean Murray Carret & Co. | View Related Stories »
- Morgan Joseph | View Related Stories »
- New Home Sales | View Related Stories »
- RBC Capital | View Related Stories »
- Lazard | View Related Stories »
- PAR Investment Partners | View Related Stories »
- Susquehanna International Group of Companies | View Related Stories »
- Goldman Sachs | View Related Stories »
- Crude Oil | View Related Stories »
View All Major News StreetInsider.com Major News for POZN
- POZEN (POZN) Beats Estimates by 5c, Reports Q3 EPS of $0.22
- POZEN (POZN) Reports Mixed Q2 Results
- POZEN (POZN) Tops Q1 View By 6c
View All ReportsStreetInsider.com Reports on POZN
- Trading Radar for 10/28: First Solar (FSLR), ConocoPhillips (COP), WellPoint (WLP), Goodyear (GT), Int. Paper (IP) Report
- POZEN (POZN) Beats Estimates by 5c, Reports Q3 EPS of $0.22
- POZEN (POZN) PA65020 Phase I Shows Risk Reduction in Upper Gastrodudenal Damage
- AstraZeneca (AZN) and POZEN (POZN) Announced Pivotal Data from VIMOVO Studies at ACR 2009 Meeting
- POZEN (POZN) Said Securities Class Action Lawsuit Dismissed
View All Press ReleasesCompany Press Releases on POZN
- POZEN Announces Start of Enrollment For PA32540 Phase 3 Program
- POZEN To Present at the Credit Suisse Healthcare Conference
- POZEN Reports Third Quarter 2009 Results
- Results of Phase I Study Show Novel, Investigational PA65020 Compound Significantly Decreased Risk of Upper GI Damage in Healthy Adults
- Patients Taking VIMOVO(TM) Showed a Decrease in Incidence of NSAID-Associated Ulcers
StreetInsider Reports on POZN by Category
View All BlogsBlogs on POZN
- FDA Calendar Updates: AspenBio, CytRx, Cephalon, Pozen, Sanofi, AMAG
- Marked Improvement Bodes Well for Pozen
- POZEN Q4 2008 Earnings Call Transcript
- Pozen Poised to Fill a Healthcare Void
- POZEN Inc. Q3 2008 Earnings Call Transcript
View All FilingsSEC Filings on POZN
- Form 10-Q POZEN INC /NC For: Sep 30
- Form 8-K POZEN INC /NC For: Sep 30
- Form 8-K POZEN INC /NC For: Sep 29
Comments on POZN
No comments are currently available.
